“…A series of chemical anticancer drugs have been well developed and clinically used in these decades, such as doxorubicin (DOX) (Zhang et al, 2012;Fabbri et al, 2016), paclitaxel (PTX) (Markman & Mekhail, 2002;Yang et al, 2018), and camptothecin (CPT) (Venditto & Simanek, 2010;Llin as et al, 2018); however, these drugs are limited in the further clinical applications due to the serious side-effects caused by offtargeting and low therapeutic efficacy (Jungk et al, 2016;Yoshizawa et al, 2016). To overcome these obstacles, nanoscale drug delivery systems (DDSs) have attracted more and more attention and been extensively investigated (Chen et al, 2014), such as polymeric micelles (PMs), nanoparticles (NPs), prodrug, and liposome (Zhang et al, 2016;Zylberberg & Matosevic, 2016;Huang et al, 2018;Li et al, 2018;Dong et al, 2019). These effective DDSs are used to deliver hydrophobic or hydrophilic therapeutics which exhibit poor pharmacokinetics and high cytotoxicity to the site of tumor (Wang et al, 2016;Qin et al, 2017;Li et al, 2019).…”